For research use only. Not for therapeutic Use.
Imexon(CAT: I007277) is an investigational anticancer agent. It is a small molecule compound that belongs to the class of imino pyrrolidines. Imexon has shown potential antitumor activity through multiple mechanisms, including induction of oxidative stress, inhibition of DNA synthesis, and modulation of cellular redox balance. It has been studied for the treatment of various types of cancers, including pancreatic cancer, lung cancer, and hematological malignancies. Clinical trials are underway to evaluate its safety and efficacy as a therapeutic option for cancer patients.
| Catalog Number | I007277 |
| CAS Number | 59643-91-3 |
| Synonyms | BM 06002; BM-06002; BM06002; NSC 313425; NSC313425; NSC-313425; Imexon; Amplimexon.;4-amino-1,3-diazabicyclo[3.1.0]hex-3-en-2-one |
| Molecular Formula | C4H5N3O |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term , or -20°C for long term. |
| Reference | </br>1:A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma. Cohen SJ, Zalupski MM, Conkling P, Nugent F, Ma WW, Modiano M, Pascual R, Lee FC, Wong L, Hersh E.Am J Clin Oncol. 2015 Dec 24. [Epub ahead of print] PMID: 26709865 </br>2:Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM.Blood. 2014 Aug 21;124(8):1259-65. doi: 10.1182/blood-2014-04-570044. Epub 2014 Jul 11. PMID: 25016003 Free PMC Article</br>3:Chemistry and pharmacology of imexon and related cyanoaziridines. Remers WA, Dorr RT.Curr Med Chem. 2012;19(33):5745-53. PMID: 22998528 </br>4:Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells. Sheveleva EV, Landowski TH, Samulitis BK, Bartholomeusz G, Powis G, Dorr RT.Mol Cancer Res. 2012 Mar;10(3):392-400. doi: 10.1158/1541-7786.MCR-11-0359. Epub 2012 Jan 24. PMID: 22275514 Free PMC Article</br>5:Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells. Samulitis BK, Dorr RT, Chow HH.Anticancer Res. 2011 Sep;31(9):2781-5. PMID: 21868520 </br>6:Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma. Moehler TM, Feneberg R, Ho AD, Golenkov AK, Ludwig H, Kropff M, Khuageva NK, Hajda J, von Broen I, Goldschmidt H.Anticancer Drugs. 2010 Aug;21(7):708-15. doi: 10.1097/CAD.0b013e32833b975b. PMID: 20571355 </br>7:A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O/’Day S, Sato T, Dorr R, Grenier K, Hersh E.Cancer. 2010 Aug 1;116(15):3683-91. doi: 10.1002/cncr.25119. PMID: 20564083 Free Article</br>8:Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. Roman NO, Samulitis BK, Wisner L, Landowski TH, Dorr RT.Cancer Chemother Pharmacol. 2011 Jan;67(1):183-92. doi: 10.1007/s00280-010-1306-0. Epub 2010 Mar 26. PMID: 20339847 Free PMC Article</br>9:Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study. Cho H, Koto M, Riesterer O, Molkentine DP, Giri U, Milas L, Story MD, Ha CS, Raju U.Anticancer Res. 2009 Nov;29(11):4409-15. PMID: 20032386 Free Article</br>10:A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cohen SJ, Zalupski MM, Modiano MR, Conkling P, Patt YZ, Davis P, Dorr RT, Boytim ML, Hersh EM.Cancer Chemother Pharmacol. 2010 Jul;66(2):287-94. doi: 10.1007/s00280-009-1162-y. Epub 2009 Oct 24. PMID: 19855966 Free PMC Article |
